A. Questionnaire and H. , 144 13.1. Annexe 1 : Grille de recueil 144 13.2 Annexe 2 : Score de Charlson (68) 148 13.3 Annexe 3 : Score RDCI (69), Questionnaire SF-36, p.154

Y. Alamanos and A. Drosos, Epidemiology of adult rheumatoid arthritis, Autoimmunity Reviews, vol.4, issue.3, p.1306, 2005.
DOI : 10.1016/j.autrev.2004.09.002

L. Carmona, J. Ballina, R. Gabriel, and A. Laffon, The burden of musculoskeletal diseases in the general population of Spain: results from a national survey, Annals of the Rheumatic Diseases, vol.60, issue.11, p.10405, 2001.
DOI : 10.1136/ard.60.11.1040

F. Guillemin, Prevalence of rheumatoid arthritis in France, Ann Rheum Dis, vol.64, p.142730, 2001.

S. Gabriel and K. Michaud, Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases, Arthritis Research & Therapy, vol.11, issue.3, p.229, 2009.
DOI : 10.1186/ar2669

D. Aletaha, T. Neogi, A. Silman, J. Funovits, D. Felson et al., Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative CRI-net.com -Club Rhumatismes et Inflammations, Arthritis Rheum, vol.62, issue.8, p.256981, 2010.

F. Arnett, S. Edworthy, D. Bloch, D. Mcshane, J. Fries et al., The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis & Rheumatism, vol.143, issue.3, p.31524, 1988.
DOI : 10.1002/art.1780310302

J. Kay and K. Upchurch, ACR/EULAR 2010 rheumatoid arthritis classification criteria, Rheumatology, vol.51, issue.suppl 6
DOI : 10.1093/rheumatology/kes279

URL : https://academic.oup.com/rheumatology/article-pdf/51/suppl_6/vi5/5056206/kes279.pdf

A. Eular, J. Smolen, R. Landewé, J. Bijlsma, G. Burmester et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2016 update, Ann Rheum Dis. Ann Rheum Dis, vol.7076, issue.6, pp.94955-94968, 1987.

/. Tnf_dec2010, M. Soubrier, A. Antunez, P. Balint, A. Balsa et al., Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, crosssectional study (COMORA), Ann Rheum Dis, vol.73, p.628, 2014.

K. Michaud and F. Wolfe, Comorbidities in rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, vol.21, issue.5, p.885906, 2007.
DOI : 10.1016/j.berh.2007.06.002

H. Radner, K. Yoshida, M. Frits, C. Iannaccone, N. Shadick et al., The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient Development and Validation of a, Rheumatology. Ann Rheum Dis, vol.5470, 2011.

S. Ramiro, C. Gaujoux-viala, J. Nam, J. Smolen, M. Buch et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis Tolerance and effectiveness of anti?tumor necrosis factor ? therapies in elderly patients with rheumatoid arthritis: A population-based cohort study al. Anti?tumor necrosis factor ? therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis, Ann Rheum Dis. Arthritis Care Res. Arthritis Rheum, vol.735756, issue.25, p.67985175464, 2007.

J. Galloway, K. Hyrich, L. Mercer, W. Dixon, B. Fu et al., Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis, Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis, pp.1289952530-1289952559, 2011.

B. Seriolo, C. Ferrone, and M. Cutolo, Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity, J Rheumatol, vol.35, p.3557, 2008.

F. Ursini, D. Mauro, S. Naty, D. Gagliardi, R. Grembiale et al., Improvement in insulin resistance after short-term treatment with abatacept: case report and short review Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab, ):11645. 33. Wilczynska MM, Condliffe AM, McKeon DJ. Coexistence of Bronchiectasis and Rheumatoid Arthritis: Revisited. Respir Care, p.694701, 2011.

G. Caramori, I. Adcock, D. Stefano, A. Chung, and K. , Cytokine inhibition in the treatment of COPD

M. Weisman, H. Paulus, F. Burch, A. Kivitz, J. Fierer et al., A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases, Rheumatology, vol.46, issue.7, pp.397412-3511225, 2007.
DOI : 10.1093/rheumatology/kem033

M. Jani, N. Hirani, E. Matteson, and W. Dixon, The safety of biologic therapies in RA-associated interstitial lung disease, Nature Reviews Rheumatology, vol.25, issue.5, p.28494, 2013.
DOI : 10.1136/ard.2008.091926

C. Roubille, B. Haraoui, J. Curtis, A. Lanas, A. John et al., Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review Factors Associated with Gastrointestinal Perforation in a Cohort of Patients with Rheumatoid Arthritis Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review Cardiovascular death in rheumatoid arthritis: A population-based study, Semin Arthritis Rheum. Arthritis Care Res. Clin Rheumatol. Arthritis Rheum, vol.43643052, issue.40, pp.61326-381471472232, 2005.

D. Solomon, M. Peters, D. Symmons, D. Mccarey, B. Dijkmans et al., Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis, Circulation. Ann Rheum Dis, vol.10769, pp.13037-4232531, 2003.

P. Fardellone, A. Séjourné, J. Paccou, and V. Goëb, Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study, Bone Remodelling Markers in Rheumatoid Arthritis. Mediators Inflamm. Krieckaert CLM, vol.2014, pp.15-44, 2014.

/. Dec2015, S. Ohta, T. Tsuru, K. Terao, S. Mogi et al., Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study), J Clin Pharmacol, vol.54, p.10919, 2014.

E. Keystone, J. Kremer, A. Russell, J. Box, C. Abud-mendoza et al., Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.857-861, 2012.
DOI : 10.1136/annrheumdis-2011-200355

M. Weinblatt, M. Schiff, R. Valente, D. Van-der-heijde, G. Citera et al., Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase

M. Genovese, C. Tena, A. Covarrubias, G. Leon, E. Mysler et al., Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial, The Journal of Rheumatology, vol.41, issue.4, pp.629-639, 2014.
DOI : 10.3899/jrheum.130112

J. Kaine, G. Gladstein, I. Strusberg, M. Robles, I. Louw et al., Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study) Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, Ann Rheum Dis. Arthritis Care Res, vol.7165, pp.3844-5271828, 2012.

M. Schiff, R. Reggia, F. Franceschini, A. Tincani, and I. Cavazzana, Subcutaneous abatacept for the treatment of rheumatoid arthritis Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety, Rheumatology. J Rheumatol, vol.5242, pp.98697-54, 1935.

A. Ogata, T. Atsumi, T. Fukuda, Y. Hirabayashi, M. Inaba et al., Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study) al. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA), Disponible sur WHO | ADHERENCE TO LONG-TERM THERAPIES: EVIDENCE FOR ACTION [Internet], pp.135462-5734454, 2014.

S. Schwartzman, G. Morgan, and T. Fahey, Does route of administration affect the outcome of TNF antagonist therapy?):1923. 63. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis How do patients' treatment preferences compare with those of clinicians? Qual Health Care QHC, Arthritis Res Ther. Musculoskeletal Care, vol.6610, issue.21, 2001.

Y. Yazici, B. Mcmorris, T. Darkow, and L. Rosenblatt, Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis, Clin Exp Rheumatol, vol.27, pp.907-913, 2009.

J. Fries, P. Spitz, R. Kraines, and H. Holman, Measurement of patient outcome in arthritis, Disease Comorbidity Index, p.86572, 1980.
DOI : 10.1001/jama.1963.03060120024016

S. Monti, C. Klersy, R. Gorla, P. Sarzi-puttini, F. Atzeni et al., Factors influencing the choice of first-and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry, Clin Rheumatol, vol.36, p.75361, 2017.

J. Al-bishri, S. Attar, N. Bassuni, Y. Al-nofaiey, H. Qutbuddeen et al., Baseline Comorbidities in a Population-Based Cohort of Rheumatoid Arthritis Patients Receiving Biological Therapy: Data from the Australian Rheumatology Association Database Considering Patient Preferences When Selecting Anti?Tumor Necrosis Factor Therapeutic Options Am Health Drug Benefits Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease Estimating Effectiveness and Cost of Biologics for Rheumatoid Arthritis: Application of a Validated Algorithm to Commercial Insurance Claims Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis, Comorbidity Profile Among Patients with Rheumatoid Arthritis and the Impact on Prescriptions Trend al. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, twocohort PrefHer study, pp.118-7418, 2009.

. Dans-le-cadre-de-votre-polyarthrite-rhumatoïde, vous a-t-on déjà proposé de passer des injections intraveineuses, en Hôpital de Jour, aux injections sous-cutanées à domicile pour votre biomédicament ?

S. Oui, vous rappelez-vous de quand cela date approximativement ? Moins de 6 mois Entre 6 mois et 1 an Plus d'un an Non concerné(e)

A. Si and . ????????????????????????????????????, exercez-vous une profession ? Oui Non 12

. Si-non, êtes-vous en arrêt de travail ? Oui Non 14. Êtes-vous retraité(e) ? Oui Non

C. La, en charge vos déplacements en Hôpital de Jour ? Oui Non 20 Actuellement êtes-vous : Marié(e) En couple Célibataire Veuf / Veuve 21. Avez-vous des enfants ? Oui Non 22. Si oui, combien ? ??????????????????????????????????????? 23